Safety Findings for Axi-Cel in Patients With DLBCL

Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, a physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic, discussesthe safety findingsfrom the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.

In addition to the efficacy results that demonstrated a complete remission rate around 40% and an overall response rate even higher, the safety findings are comparable to what has been previously seen. Hill says this is in terms of cytokine release syndrome and encephalopathy.